In CMC, Drug Substance (DS) is the active material (API for small molecules; the active biological substance for biologics), and Drug Product (DP) is the finished dosage form in its final container-closure system that is administered to the patient. DS and DP have distinct manufacturing descriptions, control strategies, specifications, and stability programs. Regulatory submissions in the CTD are explicitly separated: Module 3.2.S (DS) and Module 3.2.P (DP).
Drug Substance (DS)
The Drug Substance is the purified active material prior to formulation into the final product.
- Small molecules: DS is the Active Pharmaceutical Ingredient (API).
- Biologics (e.g., mAbs): DS is the purified monoclonal antibody bulk after downstream processing (e.g., chromatography, UF/DF), typically held under controlled conditions (often refrigerated or frozen). It is not yet in the final container-closure system and not claimed sterile (sterility is ensured at the DP stage).
- AAV gene therapy: DS is the purified AAV vector bulk after downstream processing (e.g., capture/polishing chromatography and UF/DF), typically stored frozen at defined conditions.
Defining Drug Product (DP)
The Drug Product is the finished form containing the DS plus excipients, placed in its final container-closure system with the intended strength and labeling for clinical use.
- mAbs: DP is the formulated antibody (buffer/excipients) brought to target concentration, then sterility-assured (e.g., sterile filtration and aseptic fill) and filled into vials/syringes.
- AAV gene therapy: DP is the final formulated vector at labeled titer in the final vials/syringes, produced via aseptic operations. (Dilution from DS may or may not be required, depending on process/design.)
Why the Distinction Matters in CMC?
- Separate manufacturing processes and descriptions: DS covers upstream/downstream purification and bulk handling; DP covers formulation, aseptic processing/fill-finish, and packaging.
- Separate specifications: DS and DP have different test panels and acceptance criteria.
- DS specs focus on identity, purity/impurities, potency/activity (as applicable), concentration, and bioburden/endotoxin controls appropriate for bulk.
- DP specs additionally include appearance, extractable/particulate matter (as applicable), sterility/BACT, endotoxin, and other container-closure–related attributes; acceptance criteria are set for the final, labeled presentation.
- Separate stability programs:
- DS stability supports bulk hold time and storage conditions (e.g., frozen hold).
- DP stability establishes the clinical/commercial shelf-life under labeled storage (including in-use/hold times if applicable).
Regulatory Guidance:
- CTD structure:
- Module 3.2.S – Drug Substance (manufacture, control strategy, specs, stability for DS)
- Module 3.2.P – Drug Product (formulation, manufacturing/aseptic processing, container-closure, control strategy, specs, stability for DP)
- ICH Q6B – Specifications: Guidance on setting and justifying biotech/biological DS vs DP specifications, including test selection and acceptance criteria.
- ICH Q1A(R2) – Stability Testing of New Drug Substances and Products (small molecules): Principles for chemical entities’ DS/DP stability programs.
- ICH Q5C – Stability Testing of Biotechnological/Biological Products: Stability expectations for biologics (e.g., proteins, recombinant products), including considerations applicable to bulk (DS) and finished product (DP).